S. Goldberg

8.7k total citations
15 papers, 439 citations indexed

About

S. Goldberg is a scholar working on Immunology, Oncology and Genetics. According to data from OpenAlex, S. Goldberg has authored 15 papers receiving a total of 439 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Immunology, 4 papers in Oncology and 3 papers in Genetics. Recurrent topics in S. Goldberg's work include Immunotherapy and Immune Responses (6 papers), T-cell and B-cell Immunology (4 papers) and Cancer Immunotherapy and Biomarkers (4 papers). S. Goldberg is often cited by papers focused on Immunotherapy and Immune Responses (6 papers), T-cell and B-cell Immunology (4 papers) and Cancer Immunotherapy and Biomarkers (4 papers). S. Goldberg collaborates with scholars based in United States, Italy and Germany. S. Goldberg's co-authors include Jedd D. Wolchok, Alan N. Houghton, Mary Jo Turk, José A. Guevara-Patiño, Miguel‐Angel Perales, Cristina R. Ferrone, Susan Parker, Manuel E. Engelhorn, Omid Hamid and Hiroshi Uchi and has published in prestigious journals such as Journal of Clinical Oncology, Immunity and Clinical Cancer Research.

In The Last Decade

S. Goldberg

15 papers receiving 428 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S. Goldberg United States 11 288 182 124 63 37 15 439
Kei Haniuda Japan 11 449 1.6× 70 0.4× 147 1.2× 51 0.8× 27 0.7× 22 607
Jennifer B. Jacob United States 13 293 1.0× 159 0.9× 194 1.6× 105 1.7× 29 0.8× 21 500
Jean‐Nicolas Schickel United States 10 307 1.1× 68 0.4× 110 0.9× 39 0.6× 31 0.8× 12 438
L.M. Shlapatska Ukraine 12 358 1.2× 146 0.8× 131 1.1× 17 0.3× 50 1.4× 25 498
Anne M. King United States 11 260 0.9× 107 0.6× 130 1.0× 29 0.5× 81 2.2× 14 480
Aline Martayan Italy 13 287 1.0× 122 0.7× 148 1.2× 45 0.7× 12 0.3× 24 546
Hart S. Dengler United States 7 448 1.6× 101 0.6× 249 2.0× 25 0.4× 32 0.9× 7 666
Nicholas A. Zorko United States 11 176 0.6× 165 0.9× 104 0.8× 28 0.4× 78 2.1× 31 470
Xingwen Dong United States 9 224 0.8× 83 0.5× 266 2.1× 34 0.5× 33 0.9× 15 528
Ashley Knights Australia 13 498 1.7× 322 1.8× 269 2.2× 21 0.3× 47 1.3× 15 705

Countries citing papers authored by S. Goldberg

Since Specialization
Citations

This map shows the geographic impact of S. Goldberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Goldberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Goldberg more than expected).

Fields of papers citing papers by S. Goldberg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Goldberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Goldberg. The network helps show where S. Goldberg may publish in the future.

Co-authorship network of co-authors of S. Goldberg

This figure shows the co-authorship network connecting the top 25 collaborators of S. Goldberg. A scholar is included among the top collaborators of S. Goldberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Goldberg. S. Goldberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Gutierrez, Martin, Agnieszka Woźniak, Corey J. Langer, et al.. (2018). P2.01-42 Impact of Tobacco Smoking on Outcomes in Patients with Metastatic Non-Small Cell Lung Cancer in the Era of Targeted Therapy. Journal of Thoracic Oncology. 13(10). S680–S681. 1 indexed citations
2.
Weber, Jeffrey S., Omid Hamid, Asim Amin, et al.. (2013). Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma.. PubMed Central. 58 indexed citations
3.
Godwin, John E., Izidore S. Lossos, Michael E. Williams, et al.. (2013). A phase Ib, open-label, multicenter study of urelumab (BMS-663513) in combination with rituximab in subjects with relapsed/refractory B-cell malignancies.. Journal of Clinical Oncology. 31(15_suppl). TPS3108–TPS3108. 10 indexed citations
4.
5.
Tykodi, Scott S., Julie R. Brahmer, Wen‐Jen Hwu, et al.. (2012). PD-1/PD-L1 pathway as a target for cancer immunotherapy: Safety and clinical activity of BMS-936559, an anti-PD-L1 antibody, in patients with solid tumors.. Journal of Clinical Oncology. 30(15_suppl). 2510–2510. 22 indexed citations
6.
Faderl, Stefan, Meir Wetzler, David A. Rizzieri, et al.. (2011). Clofarabine plus cytarabine compared to cytarabine alone in older patients with relapsed or refractory (R/R) acute myelogenous leukemia (AML): Results from the phase III CLASSIC 1 trial.. Journal of Clinical Oncology. 29(15_suppl). 6503–6503. 6 indexed citations
7.
Mato, Anthony R., Tatyana Feldman, Pritish K. Bhattacharyya, et al.. (2010). The association between the Mantle Cell Lymphoma International Prognostic Index (MIPI) and survival in patients treated with rituximab-HCVAD (RHCVAD) alternating with rituximab-methotrexate-AraC (R-MTX-AraC).. Journal of Clinical Oncology. 28(15_suppl). 8092–8092. 3 indexed citations
8.
Uchi, Hiroshi, Rodica Stan, Mary Jo Turk, et al.. (2006). Unraveling the Complex Relationship Between Cancer Immunity and Autoimmunity: Lessons from Melanoma and Vitiligo. Advances in immunology. 90. 215–241. 54 indexed citations
9.
Hochhaus, Andreas, Hagop M. Kantarjian, Michele Baccarani, et al.. (2006). Dasatinib in patients with chronic phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to imatinib: Results of the CA180013 ’START-C’ Study. Journal of Clinical Oncology. 24(18_suppl). 6508–6508. 20 indexed citations
10.
Ferrone, Cristina R., Miguel‐Angel Perales, S. Goldberg, et al.. (2006). Adjuvanticity of Plasmid DNA Encoding Cytokines Fused to Immunoglobulin Fc Domains. Clinical Cancer Research. 12(18). 5511–5519. 41 indexed citations
11.
Goldberg, S., Shirley Bartido, Jason P. Gardner, et al.. (2005). Comparison of Two Cancer Vaccines Targeting Tyrosinase: Plasmid DNA and Recombinant Alphavirus Replicon Particles. Clinical Cancer Research. 11(22). 8114–8121. 48 indexed citations
12.
Cortes, Jörge E., Francis J. Giles, August J. Salvado, et al.. (2005). High-dose (HD) imatinib in patients (pts) with previously untreated chronic myeloid leukemia (CML) in early chronic phase (CP): preliminary results of a multicenter community based trial. Journal of Clinical Oncology. 23(16_suppl). 6518–6518. 9 indexed citations
13.
Trcka, Jiri, Yoichi Moroi, Raphael Clynes, et al.. (2002). Redundant and Alternative Roles for Activating Fc Receptors and Complement in an Antibody-Dependent Model of Autoimmune Vitiligo. Immunity. 16(6). 861–868. 59 indexed citations
14.
Perales, Miguel‐Angel, Giamila Fantuzzi, S. Goldberg, et al.. (2002). GM-CSF DNA induces specific patterns of cytokines and chemokines in the skin: implications for DNA vaccines. PubMed. 7(3). 125–133. 27 indexed citations
15.
Turk, Mary Jo, Jedd D. Wolchok, José A. Guevara-Patiño, S. Goldberg, & Alan N. Houghton. (2002). Multiple pathways to tumor immunity and concomitant autoimmunity. Immunological Reviews. 188(1). 122–135. 68 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kei Haniuda Breakdown of academic impact, for papers by Jennifer B. Jacob Breakdown of academic impact, for papers by Jean‐Nicolas Schickel Breakdown of academic impact, for papers by L.M. Shlapatska Breakdown of academic impact, for papers by Anne M. King Breakdown of academic impact, for papers by Aline Martayan Breakdown of academic impact, for papers by Hart S. Dengler Breakdown of academic impact, for papers by Nicholas A. Zorko Breakdown of academic impact, for papers by Xingwen Dong Breakdown of academic impact, for papers by Ashley Knights
Rankless by CCL
2026